Are the New Oral GLP-1 Pills (Orforglipron and Danuglipron) Safe and Effective? A Meta-Analysis of Seven Trials
Oral GLP-1 pills orforglipron and danuglipron significantly lowered blood sugar and body weight in early trials, with GI side effects as the main tradeoff.
Quick Facts
What This Study Found
This meta-analysis of seven randomized controlled trials (1,037 patients total) found that the oral GLP-1 receptor agonists orforglipron and danuglipron significantly reduced HbA1c by 1.03% in people with type 2 diabetes compared to placebo. Weight loss was also significant: an average of 3.26 kg in diabetes patients and 7.52 kg in people with obesity.
Importantly, the drugs did not increase the risk of severe hypoglycemia or serious adverse events. However, gastrointestinal side effects were about 2.6 times more likely, and patients were about 2.9 times more likely to stop treatment due to adverse events.
Key Numbers
How They Did This
The researchers conducted a systematic review and meta-analysis, searching PubMed, Cochrane Library, and Scopus for all randomized controlled trials of orforglipron and danuglipron published through August 2023. Two independent reviewers selected studies, extracted data, and assessed quality. Results from seven trials (1,037 patients) were pooled using random effects meta-analysis. All included trials were rated low risk of bias.
Why This Research Matters
Most GLP-1 drugs like semaglutide and tirzepatide require injections. Orforglipron and danuglipron are small-molecule pills that activate the same GLP-1 receptor, which could make this class of medication far more accessible. This meta-analysis provides the first pooled look at whether these oral alternatives actually work — and suggests they do, with a safety profile broadly similar to injectable GLP-1 drugs.
The Bigger Picture
The GLP-1 drug revolution has been driven by injectables like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). But many patients avoid or can't use needles. Orforglipron and danuglipron represent a fundamentally different approach — small-molecule pills that don't need the absorption enhancers that oral semaglutide (Rybelsus) requires. This meta-analysis offers early reassurance that the pill-based approach works, though larger and longer trials are needed to know how they truly stack up against the injectables.
What This Study Doesn't Tell Us
The analysis included only seven trials with a combined 1,037 patients — a relatively small pool. Most trials were short-term, so long-term efficacy and safety remain unknown. The wide confidence interval for weight loss in people with obesity (ranging from -0.41 to -14.63 kg) suggests high variability. No data on cardiovascular outcomes or other hard endpoints were available.
Questions This Raises
- ?How will long-term cardiovascular outcomes compare between these oral GLP-1 pills and injectable GLP-1 drugs?
- ?Can the gastrointestinal side effects be managed well enough to improve the high discontinuation rates?
- ?Will orforglipron or danuglipron achieve the same magnitude of weight loss seen with injectable semaglutide at higher doses?
Trust & Context
- Key Stat:
- −1.03% HbA1c Average blood sugar reduction with oral GLP-1 pills vs. placebo across seven randomized trials
- Evidence Grade:
- This is a systematic review and meta-analysis of randomized controlled trials — the highest level of evidence hierarchy. However, the total sample size is modest (1,037 patients) and the included trials were relatively short-term, which limits confidence in long-term conclusions.
- Study Age:
- Published in 2023, this meta-analysis covers the earliest clinical trial data for orforglipron and danuglipron. Since then, larger phase 3 trials have reported results, so this represents a useful early snapshot rather than the final word.
- Original Title:
- Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
- Published In:
- Metabolism: clinical and experimental, 149, 155710 (2023)
- Authors:
- Karakasis, Paschalis(7), Patoulias, Dimitrios(10), Pamporis, Konstantinos(2), Stachteas, Panagiotis, Bougioukas, Konstantinos I, Klisic, Aleksandra, Fragakis, Nikolaos, Rizzo, Manfredi
- Database ID:
- RPEP-07030
Evidence Hierarchy
Frequently Asked Questions
How are orforglipron and danuglipron different from oral semaglutide (Rybelsus)?
Oral semaglutide is still a large peptide molecule that needs a special absorption enhancer (SNAC) and must be taken on an empty stomach with limited water. Orforglipron and danuglipron are small-molecule drugs that activate the same GLP-1 receptor but don't have the same absorption restrictions, making them potentially easier to take.
Are the stomach side effects the same as with injectable GLP-1 drugs?
The types of side effects are similar — mainly nausea, vomiting, and diarrhea. This meta-analysis found patients on oral GLP-1 pills were about 2.6 times more likely to experience GI issues and nearly 3 times more likely to stop treatment because of side effects, which is broadly consistent with the injectable GLP-1 class.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07030APA
Karakasis, Paschalis; Patoulias, Dimitrios; Pamporis, Konstantinos; Stachteas, Panagiotis; Bougioukas, Konstantinos I; Klisic, Aleksandra; Fragakis, Nikolaos; Rizzo, Manfredi. (2023). Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.. Metabolism: clinical and experimental, 149, 155710. https://doi.org/10.1016/j.metabol.2023.155710
MLA
Karakasis, Paschalis, et al. "Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.." Metabolism: clinical and experimental, 2023. https://doi.org/10.1016/j.metabol.2023.155710
RethinkPeptides
RethinkPeptides Research Database. "Safety and efficacy of the new, oral, small-molecule, GLP-1 ..." RPEP-07030. Retrieved from https://rethinkpeptides.com/research/karakasis-2023-safety-and-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.